THE WOODLANDS, Texas, Sept. 20, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has commenced the dosing of the final cohort in its Phase 2 low-dose trial of oral Proellex. The current group will receive 12mg per day, the highest dose level in the trial. Following expected completion of the study this year, Repros plans to request an end of Phase 2 meeting with the FDA during the first half of 2012 in order to discuss the commencement of limited Phase 3 studies for the use of oral Proellex in the treatment of endometriosis. To date, there have been no signals of adverse effects on the liver for oral doses of Proellex seen in patients who have received the drug in the trial. The study is designed to provide rigorous assessment of the impact of the drug on menstrual events, as well as liver function.
